List of Cell Therapies Companies in South Korea - 18

AbClon was founded in 2010 by a consortium of Korean and Swedish experts in antibody development. Our mission is to cure once incurable diseases such as cancer.

bBHC Stem Cell Treatment & Research Institute discovered the newly Elicited pluripotent Stem Cell without side effects which is called nEPS. We've been differentiated nEPS into endoderm,mesoderm and ectoderm. Our goal is overcome to incurable diseas using in nEPS.

Bionoxx is a research and development company that develops immune regulation-based anticancer drugs to conquer cancer diseases.

Founded in 2019, Brexogen is at the forefront of biotechnological innovation, dedicated to transforming the treatment of incurable diseases through our proprietary BG-Platform technology. As a pioneering bioventure, we specialize in the development of cell-free therapies, leveraging the untapped potential of stem cell derived exosomes. Our mission intertwines groundbreaking research with practical healthcare solutions. As we gear up for global expansion, our strategy emphasizes understanding local markets, forging strategic partnerships, continuous innovation, and engaging with the medical community to promote the benefits of exosome therapy. Rooted in South Korea, Brexogen is on a trajectory to enhance healthcare outcomes worldwide. We're dedicated to leading the charge in biotechnological innovation, offering accessible, effective treatments on a global scale. Join our journey as we strive for a healthier future across communities globally.

Cellatose Therapeutics Co., Ltd. is a company specializing in cell therapy development that was established in August 2017 with the goal of ‘ resolving unmet needs for incurable diseases . ’ The nation's best cell therapy research and development experts are gathering to discover differentiated cell and platform technologies and promote the commercialization of cell therapy products.

CorestemChemon is a global biotechnology corporation centered on stem cell-based new drug development and non-clinical research divisions. Motivated by the urgent need for medication for patients, the bio-pharmaceuticals division remains dedicated to research and development. In 2014, the unit successfully commercialized Neuronata-R inj, a stem cell therapy for the rare disease Amyotrophic Lateral Sclerosis (ALS), making it the fifth stem cell therapy approved for use globally. Alongside ALS treatment, the division has pipelines for various diseases such as lupus, Neuromyelitis Optica (NMO), and multiple system atrophy (MSA). Leveraging the success of the ALS stem cell therapy, the unit plans to concentrate on developing treatments for rare and incurable neurological and autoimmune diseases to dominate new market.

Curamys is a biotechnology company that develops cell fusion technology to cure intractable diseases.

Curocell is a cell therapy company that discovers and develops CAR-T therapies for cancer. The company's current efforts focus on unleashing the body’s immune system through broad-spectrum CAR-T technologies to treat blood cancers, as well as solid cancers. The company's programmed T cell product candidates are differentiated by incorporation of T cell modifying technology designed to effectively overcoming the immune suppression, and thereby offers greater efficacy compared to the current CAR-T cell technology.

InnobationBio Co., Ltd., headquartered in the Republic of Korea, is a biotechnology company having established two major platforms. Its R&D capabilities are utilized to develop antibody and cell immunotherapy for cancer treatment, as well as liquid biopsy-based biomarkers.

Korea University is a higher education institution that offers academic programs and conducts research.

MEDIPOST is founded in 2000, and today MEDIPOST is leading the global stem cell therapeutics field with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee Osteoarthritis(OA), launched in Korean market in 2012. MEDIPOST operates the largest private cord blood bank “CELLTREE®” in Korea with over 255,000 units of private cord blood units under storage. Each year, over 20,000 private cord blood units are collected and stored at CELLTREE®. MEDIPOST’s research and development is focused on novel off-the-shelf, allogeneic cell therapeutics using human Umbilical Cord Blood-derived Mesenchymal Stromal Cells (hUCB-MSCs) with clinical-stage assets in the disease areas of osteoarthritis (OA), broncho-pulmonary dysplasia (BPD) and Alzheimer’s disease (AD). MEDIPOST’s flagship product, CARTISTEM® (allogeneic Umbilical Cord Blood-derived MSCs + hyaluronic acid hydrogel composite) for knee osteoarthritis was approved in 2012 by Korea’s regulatory agency Ministry of Food and Drug Safety (MFDS) with Biologics License Application (BLA) label “Treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma (without age limit)” PNEUMOSTEM® (allogeneic Umbilical Cord Blood-derived MSCs) for the prevention of Bronchopulmonary Dysplasia (BPD) in premature infants, completed the first-in-human Phase I safety trial in Korea and the randomized, placebo-controlled Phase II clinical trial is ongoing in Korea. Phase I/II clinical trial in the U.S. has been completed confirming safety with positive efficacy signals. MEDIPOST’s 2nd generation human Umbilical Cord Blood-derived Mesenchymal Stromal Cell (hUCB-MSC) pipeline code named SMUP-IA-01 is an off-the-shelf intra-articular injectable cell product for the patients with early to mid-stage knee osteoarthritis (OA).

Sungkyunkwan University is a higher education institution that provides academic programs and conducts research.

Therabest is a biopharmaceutical company that develops iPSC-derived immune cells. Our mission is to provide the benefits of cell therapy to many patients. We established a robust process that manufacture Armored iPSC CAR-NK, off-the-shelf cell products using our exclusive technology. Currently, our main pipeline is CD19 (Lymphoid tumor) and Muc1c (Solid tumor). We plan to expand our pipeline through collaboration with companies that own tumor target scFv.

ViGenCell is a medical company that specializes in immune cell therapy.